Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Neirita Hazarika. (2021) Acne vulgaris: new evidence in pathogenesis and future modalities of treatment. Journal of Dermatological Treatment 32:3, pages 277-285.
Read now
Read now
Isabel Cristina Valente Duarte De Sousa. (2019) New and emerging drugs for the treatment of acne vulgaris in adolescents. Expert Opinion on Pharmacotherapy 20:8, pages 1009-1024.
Read now
Read now
Ilknur Tugal-Tutkun, Carlos Pavesio, Agnès De Cordoue, Oana Bernard-Poenaru & Ahmet Gül. (2018) Use of Gevokizumab in Patients with Behçet’s Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocular Immunology and Inflammation 26:7, pages 1023-1033.
Read now
Read now
Emmanuelle C. Landmann & Ulrich A. Walker. (2017) Pharmacological treatment options for cryopyrin-associated periodic syndromes. Expert Review of Clinical Pharmacology 10:8, pages 855-864.
Read now
Read now
Ilknur Tugal-Tutkun$suffix/text()$suffix/text(), Sibel Kadayifcilar$suffix/text()$suffix/text(), Moncef Khairallah$suffix/text()$suffix/text(), Sung Chul Lee$suffix/text()$suffix/text(), Pinar Ozdal, Yilmaz Özyazgan, Ji Hun Song$suffix/text()$suffix/text(), Hyeong Gon Yu$suffix/text()$suffix/text(), Valerie Lehner$suffix/text()$suffix/text(), Agnès de Cordoue$suffix/text()$suffix/text(), Oana Bernard$suffix/text()$suffix/text() & Ahmet Gül$suffix/text()$suffix/text(). (2017) Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study. Ocular Immunology and Inflammation 25:1, pages 62-70.
Read now
Read now
Debashree Mukherjea, Sumana Ghosh, Puspanjali Bhatta, Sandeep Sheth, Srinivasan Tupal, Vikrant Borse, Thomas Brozoski, Kelly E Sheehan, Leonard P Rybak & Vickram Ramkumar. (2015) Early investigational drugs for hearing loss. Expert Opinion on Investigational Drugs 24:2, pages 201-217.
Read now
Read now
Isabel Cristina Valente Duarte de Sousa. (2014) Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opinion on Investigational Drugs 23:10, pages 1389-1410.
Read now
Read now
Kalliopi Pafili, Nikolaos Papanas & Efstratios Maltezos. (2014) Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?. Expert Opinion on Investigational Drugs 23:9, pages 1277-1284.
Read now
Read now
Nicholas A Barnes, Maya H Buch & Michael F McDermott. (2013) Use of gevokizumab for the treatment of Behçet's disease. Expert Opinion on Orphan Drugs 1:9, pages 755-763.
Read now
Read now
Gloria López-Castejón & Pablo Pelegrín. (2012) Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opinion on Investigational Drugs 21:7, pages 995-1007.
Read now
Read now
Articles from other publishers (54)
Naoki Takemura. (2023) Development of Anti-inflammatory Drugs with Novel Mechanisms of Action Targeting Pyroptosisパイロトーシスを標的とする新たな機序で働く抗炎症薬の開発. YAKUGAKU ZASSHI 143:12, pages 997-1003.
Crossref
Crossref
Naomi Schlesinger, Michael H. Pillinger, Lee S. Simon & Peter E. Lipsky. (2023) Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Elizabeth England, D. Gareth Rees, Ian Christopher Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin D. Strain, Benjamin P. Kemp, Dominic J. Corkill, Richard D. May, Katherine A. Vousden, Robin J. Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley & E. Suzanne Cohen. (2023) Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Scientific Reports 13:1.
Crossref
Crossref
Rohan Diwanji, Neil A. O'Brien, Jiyoung E. Choi, Beverly Nguyen, Tyler Laszewski, Angelo L. Grauel, Zheng Yan, Xin Xu, Jincheng Wu, David A. Ruddy, Michelle Piquet, Marc R. Pelletier, Alexander Savchenko, LaSalette Charette, Vanessa Rodrik-Outmezguine, Jason Baum, John M. Millholland, Connie C. Wong, Anne-Marie Martin, Glenn Dranoff, Iulian Pruteanu-Malinici, Viviana Cremasco, Catherine Sabatos-Peyton & Pushpa Jayaraman. (2023) Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses. Cancer Immunology Research 11:6, pages 777-791.
Crossref
Crossref
Aki Tanabe & Kouhei Tsumoto. 2023. Computer-Aided Antibody Design. Computer-Aided Antibody Design
409
433
.
Dennis D. Arnold, Ayla Yalamanoglu & Onur Boyman. (2022) Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. Frontiers in Immunology 13.
Crossref
Crossref
Mabel T. Y. Wong, Sebastian Kelm, Xiaofeng Liu, Richard D. Taylor, Terry Baker & Jonathan W. Essex. (2022) Higher Affinity Antibodies Bind With Lower Hydration and Flexibility in Large Scale Simulations. Frontiers in Immunology 13.
Crossref
Crossref
Ewelina Firlej, Wioleta Kowalska, Karolina Szymaszek, Jacek Roliński & Joanna Bartosińska. (2022) The Role of Skin Immune System in Acne. Journal of Clinical Medicine 11:6, pages 1579.
Crossref
Crossref
Alexandria O. Starks, John Owen & Jonathan Isaacs. (2022) Evaluation of the Induced Membrane for Neurotrophic Factors. The Journal of Hand Surgery 47:2, pages 130-136.
Crossref
Crossref
Agnieszka Kielczewska, Igor D'Angelo, Maria Sheena Amador, Tina Wang, Athena Sudom, Xiaoshan Min, Palaniswami Rathanaswami, Craig Pigott & Ian N. Foltz. (2022) Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence–based affinity maturation. Journal of Biological Chemistry 298:2, pages 101533.
Crossref
Crossref
Amod Gupta. 2022. Biomedical Translational Research. Biomedical Translational Research
67
124
.
Hana Malcova, Zuzana Strizova, Tomas Milota, Ilja Striz, Anna Sediva, Dita Cebecauerova & Rudolf Horvath. (2021) IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives. Frontiers in Immunology 11.
Crossref
Crossref
Hana Malcova, Tomas Milota, Zuzana Strizova, Dita Cebecauerova, Ilja Striz, Anna Sediva & Rudolf Horvath. (2021) Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?. Frontiers in Pharmacology 11.
Crossref
Crossref
Haixia Chen & Qirou Wang. 2021. Structure and Health Effects of Natural Products on Diabetes Mellitus. Structure and Health Effects of Natural Products on Diabetes Mellitus
33
55
.
Wuqian Mai & Yuhua Liao. (2020) Targeting IL-1β in the Treatment of Atherosclerosis. Frontiers in Immunology 11.
Crossref
Crossref
Tracey L. Freeman & Talia H. Swartz. (2020) Targeting the NLRP3 Inflammasome in Severe COVID-19. Frontiers in Immunology 11.
Crossref
Crossref
Zhenhua Li, Shiqi Hu, Ke Huang, Teng Su, Jhon Cores & Ke Cheng. (2020) Targeted anti–IL-1β platelet microparticles for cardiac detoxing and repair. Science Advances 6:6, pages eaay0589.
Crossref
Crossref
Fei Deng, Azim Arman, Ewa M. Goldys, Mark R. Hutchinson & Guozhen Liu. (2019) A Method for in Vivo Quantification Of Cytokine IL-1β In The Rat Intrathecal Space. ACS Applied Bio Materials 3:1, pages 539-546.
Crossref
Crossref
Desmond B. Teo & Gim Gee Teng. 2020. Diabetes Mellitus. Diabetes Mellitus
317
343
.
Alessandra Bettiol, Elena Silvestri, Gerardo Di Scala, Amedeo Amedei, Matteo Becatti, Claudia Fiorillo, Giuseppe Lopalco, Carlo Salvarani, Luca Cantarini, Alessandra Soriano & Giacomo Emmi. (2019) The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review. Rheumatology International 39:6, pages 971-990.
Crossref
Crossref
Kristine A. Smith, Abigail Pulsipher, David A. Gabrielsen & Jeremiah A. Alt. (2018) Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions. American Journal of Rhinology & Allergy 32:5, pages 412-423.
Crossref
Crossref
Alexander So, Alexandre Dumusc & Sonia Nasi. (2018) The role of IL-1 in gout: from bench to bedside. Rheumatology 57:suppl_1, pages i12-i19.
Crossref
Crossref
Amélie Moreau, Marc Le Vée, Elodie Jouan, Claire Denizot, Yannick Parmentier & Olivier Fardel. (2017) Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes. European Journal of Drug Metabolism and Pharmacokinetics 42:5, pages 871-878.
Crossref
Crossref
Najah Harouki, Lionel Nicol, Isabelle Remy-Jouet, Jean-Paul Henry, Anais Dumesnil, Annie Lejeune, Sylvanie Renet, Francesca Golding, Zoubir Djerada, Didier Wecker, Virginie Bolduc, Muriel Bouly, Jerome Roussel, Vincent Richard & Paul Mulder. (2017) The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC: Basic to Translational Science 2:4, pages 418-430.
Crossref
Crossref
Gunther Spohn, Natalia Arenas-Ramirez, Gregory Bouchaud & Onur Boyman. (2017) Endogenous polyclonal anti–IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation. Journal of Allergy and Clinical Immunology 139:6, pages 1957-1965.e3.
Crossref
Crossref
S. Könemann, M. Dörr & S.B. Felix. 2017. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases
681
714
.
Jun Zha, Xiao-wei Chi, Xiao-lin Yu, Xiang-meng Liu, Dong-qun Liu, Jie Zhu, Hui Ji & Rui-tian Liu. (2016) Interleukin-1β-Targeted Vaccine Improves Glucose Control and β-Cell Function in a Diabetic KK-Ay Mouse Model. PLOS ONE 11:5, pages e0154298.
Crossref
Crossref
Georg Schett, Jean-Michel Dayer & Bernhard Manger. (2015) Interleukin-1 function and role in rheumatic disease. Nature Reviews Rheumatology 12:1, pages 14-24.
Crossref
Crossref
Tatiana V. Cohen, Gina M. Many, Bryan D. Fleming, Viola F. Gnocchi, Svetlana Ghimbovschi, David M. Mosser, Eric P. Hoffman & Terence A. Partridge. (2015) Upregulated IL-1β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages. Skeletal Muscle 5:1.
Crossref
Crossref
Maarten Van Roy, Cedric Ververken, Els Beirnaert, Sven Hoefman, Joost Kolkman, Michel Vierboom, Elia Breedveld, Bert ‘t Hart, Sofie Poelmans, Lieselot Bontinck, Alex Hemeryck, Sandy Jacobs, Judith Baumeister & Hans Ulrichts. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Giuseppe Lopalco, Luca Cantarini, Antonio Vitale, Florenzo Iannone, Maria Grazia Anelli, Laura Andreozzi, Giovanni Lapadula, Mauro Galeazzi & Donato Rigante. (2015) Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation 2015, pages 1-21.
Crossref
Crossref
François Roubille, David Busseuil, Yanfen Shi, Walid Nachar, Téodora Mihalache-Avram, Mélanie Mecteau, Marc-Antoine Gillis, Geneviève Brand, Gabriel Théberge-Julien, Mathieu R. Brodeur, Anne-Elen Kernaleguen, Mélania Gombos, Eric Rhéaume & Jean-Claude Tardif. (2014) The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis 236:2, pages 277-285.
Crossref
Crossref
Penelope Ward & Mark Bodmer. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
851
926
.
W. Mark Abbott, Melissa M. Damschroder & David C. Lowe. (2014) Current approaches to fine mapping of antigen-antibody interactions. Immunology 142:4, pages 526-535.
Crossref
Crossref
Hassan Issafras, John A. Corbin, Ira D. Goldfine & Marina K. Roell. (2014)
Detailed Mechanistic Analysis of Gevokizumab, an Allosteric Anti–IL-1
β
Antibody with Differential Receptor-Modulating Properties
. Journal of Pharmacology and Experimental Therapeutics 348:1, pages 202-215.
Crossref
Crossref
David B. Reichling, Paul G. Green & Jon D. Levine. (2013) The fundamental unit of pain is the cell. Pain 154:Supplement 1, pages S2-S9.
Crossref
Crossref
Heather H. Shih, Paula Miller & Douglas C. Harnish. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
28
.
Ruijuan Zhao, Hongyan Zhou & Shao Bo Su. (2013) A critical role for interleukin-1β in the progression of autoimmune diseases. International Immunopharmacology 17:3, pages 658-669.
Crossref
Crossref
Marie‐Laure Bourigault, Noria Segueni, Stéphanie Rose, Nathalie Court, Rachel Vacher, Virginie Vasseur, François Erard, Marc Le Bert, Irene Garcia, Yoichiro Iwakura, Muazzam Jacobs, Bernhard Ryffel & Valerie F. J. Quesniaux. (2013)
Relative contribution of IL‐1α, IL‐1β and TNF to the host response to
Mycobacterium tuberculosis
and attenuated
M. bovis BCG
. Immunity, Inflammation and Disease 1:1, pages 47-62.
Crossref
Crossref
Monika Moll & Jasmin B. Kuemmerle-Deschner. (2013) Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology 147:3, pages 242-275.
Crossref
Crossref
Melissa J. Morine, Sinead Toomey, Fiona C. McGillicuddy, Clare M. Reynolds, Karen A. Power, John A. Browne, Christine Loscher, Kingston H.G. Mills & Helen M. Roche. (2013) Network analysis of adipose tissue gene expression highlights altered metabolic and regulatory transcriptomic activity in high-fat-diet-fed IL-1RI knockout mice. The Journal of Nutritional Biochemistry 24:5, pages 788-795.
Crossref
Crossref
Davide Foletti, Pavel Strop, Lee Shaughnessy, Adela Hasa-Moreno, Meritxell Galindo Casas, Marcella Russell, Christine Bee, Si Wu, Amber Pham, Zhilan Zeng, Jaume Pons, Arvind Rajpal & Dave Shelton. (2013) Mechanism of Action and In Vivo Efficacy of a Human-Derived Antibody against Staphylococcus aureus α-Hemolysin. Journal of Molecular Biology 425:10, pages 1641-1654.
Crossref
Crossref
Michaela Blech, Daniel Peter, Peter Fischer, Margit M.T. Bauer, Mathias Hafner, Markus Zeeb & Herbert Nar. (2013) One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β. Journal of Molecular Biology 425:1, pages 94-111.
Crossref
Crossref
Sheila SarialFarzad AsadiMahmood Jeddi-TehraniReza HadaviAli Ahmad BayatJafar MahmoudianMasoud Taghizadeh-JahedFazel ShokriHodjattallah Rabbani. (2012) A High Affinity Monoclonal Antibody Recognizing the Light Chain of Human Coagulating Factor VII. Hybridoma 31:6, pages 443-448.
Crossref
Crossref
Georgia E. Hodes & Scott J. Russo. 2012. Drug Discovery for Psychiatric Disorders. Drug Discovery for Psychiatric Disorders
159
183
.
S Ait‐Oudhia, PJ Lowe & DE Mager. (2012) Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL‐1β Kinetics. CPT: Pharmacometrics & Systems Pharmacology 1:9, pages 1-10.
Crossref
Crossref
Edward J. Wladis, Bibiana V. Iglesias, Alejandro P. Adam & Edmund J. Gosselin. (2012) Molecular Biologic Assessment of Cutaneous Specimens of Ocular Rosacea. Ophthalmic Plastic & Reconstructive Surgery 28:4, pages 246-250.
Crossref
Crossref
Masahiko Katayama, Toshitaka Sato & Junro Kuromitsu. (2012) Capture molecules preconditioned for kinetic analysis of high-affinity antigen–antibody complex in Biacore A100. Analytical Biochemistry 424:2, pages 168-177.
Crossref
Crossref
Christine Bee, Yasmina N. Abdiche, Donna M. Stone, Sierra Collier, Kevin C. Lindquist, Alanna C. Pinkerton, Jaume Pons & Arvind Rajpal. (2012) Exploring the Dynamic Range of the Kinetic Exclusion Assay in Characterizing Antigen-Antibody Interactions. PLoS ONE 7:4, pages e36261.
Crossref
Crossref
Hélène Le Buanec, Armand Bensussan, Martine Bagot, Robert C. Gallo & Daniel Zagury. 2012. Advances in Immunology Volume 115. Advances in Immunology Volume 115
187
227
.
Heather H. Shih. 2012. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics
9
32
.
Paula C. Miller & Peiling Xu. 2012. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics
355
373
.
Borbála Pazár Maldonado & Alexander So. (2011) Canakinumab for the treatment of gout. International Journal of Clinical Rheumatology 6:6, pages 605-615.
Crossref
Crossref
Thirusha Lane & Helen J. Lachmann. (2011) The Emerging Role of Interleukin-1β in Autoinflammatory Diseases. Current Allergy and Asthma Reports 11:5, pages 361-368.
Crossref
Crossref